Hadasit Bio-Holdings Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HSITF research report →
Price Chart
About the company
Hadasit Bio-Holdings Ltd, an Israeli biotechnology enterprise established in Jerusalem in 2005, focuses its efforts on critical therapeutic domains. These include oncology, regenerative medicine, and inflammatory diseases. A key offering is ProtAb, an immunotherapeutic monoclonal antibody engineered to treat autoimmune inflammatory disorders.
- CEO
- Yuval Adar
- IPO
- 2010
- Employees
- 2
- HQ
- Jerusalem, IL
Get TickerSpark's AI analysis on HSITF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.33M
- P/E
- -1.18
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 2.52
- EV/EBITDA
- -1.88
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -91.65%
- ROIC
- -72.76%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,702,000
- Net Income
- $-3,461,000+88.1%
- EPS
- $-0.31+88.2%
- OCF Growth
- +14.9%
- FCF Growth
- +14.9%
- 52W High
- $0.13
- 52W Low
- $0.12
- 50D MA
- $0.12
- 200D MA
- $0.12
- Beta
- 0.49
- RSI (14)
- 100
- Avg Volume
- 77
No earnings-call transcripts are available for HSITF yet.
- Free Float
- 25.0%
- Shares Outstanding
- 11.09M
- Float Shares
- 2.77M
Our HSITF coverage
Recent articles, reports, and earnings notes.
No research on HSITF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HSITF report →